Verdezyne

Verdezyne

closed

Industrial biotechnology company directing the power of biology to create bio-based processes for clean and sustainable chemicals.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
N/A

€0.0

round
investor investor investor

€0.0

round
investor investor investor investor

€0.0

round
N/A

€0.0

round
investor investor investor investor

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor investor investor investor

€0.0

round
*

N/A

Support Program
Total Funding000k
Notes (0)
More about Verdezyne
Made with AI
Edit

Verdezyne, founded in 2005 by G. Wesley Hatfield, Richard H. Lathrop, and Robert J. Molinari, was an industrial biotechnology firm positioned to produce renewable chemicals from non-food sources. The company's core business centered on leveraging proprietary yeast strains and fermentation processes to create cost-effective, bio-based alternatives to petrochemicals. Verdezyne's technology was feedstock-flexible, designed to metabolize various plant-based oils and their by-products, mitigating vulnerability to price and supply fluctuations associated with sugar or petroleum feedstocks.

The company's product portfolio was aimed at large, established markets. A key offering was BIOLON™ DDDA (dodecanedioic acid), a bio-based chemical intermediate used in the manufacturing of engineering polymers, automotive parts, cosmetics, and fragrances. Another commercial product, FerroShield™, was a dibasic acid mixture developed as a nitrate-free corrosion inhibitor for applications like metalworking fluids and engine coolants. Verdezyne's strategy involved forming partnerships with major chemical producers and consumers to ensure market penetration. For instance, it secured a significant off-take agreement with European distributor Will & Co for over 25% of the expected capacity of its planned Malaysian production facility for BIOLON™ DDDA.

Throughout its operation, Verdezyne raised substantial capital, totaling over $80 million from investors including Sime Darby, BP Alternative Energy Ventures, OVP Venture Partners, and Monitor Ventures. A pivotal moment was a $48 million investment led by Malaysian conglomerate Sime Darby, intended to finance technology development and a commercial-scale plant in Malaysia in partnership with Bio-XCell. This facility, dubbed "VerdePalm," was set to make Verdezyne the first commercial producer of bio-based dodecanedioic acid. However, despite the plant being near completion, the primary investor, Sime Darby, withdrew its funding. This abrupt loss of financial backing forced Verdezyne to cease operations and file for bankruptcy in 2018, leading to the liquidation of its assets.

Keywords: industrial biotechnology, renewable chemicals, synthetic biology, yeast fermentation, bio-based chemicals, dodecanedioic acid, dicarboxylic acid, corrosion inhibitors, sustainable chemicals, petrochemical alternatives, metabolic engineering, non-food feedstock, cleantech, Sime Darby, BIOLON, FerroShield, bioplastics, specialty chemicals, green chemistry, biochemicals

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo